Asset Details
Do you wish to reserve the book?
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
Do you wish to request the book?
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
2018
Overview
Background
The development of new treatments against schistosomiasis is imperative but lacks commercial interest. Drug repurposing represents a suitable strategy to identify potential treatments, which have already unblocked several essential steps along the drug development path, hence reducing costs and timelines. Promoting this approach, the Medicines for Malaria Venture (MMV) recently distributed a drug repurposing library of 400 advanced lead candidates (Stasis Box).
Methods
All 400 compounds were initially tested in vitro against the larval stage of
Schistosoma mansoni
at 10 μM. Hits progressed to screening on adult worms and were further characterised for IC
50,
cytotoxicity and selectivity. Ten lead compounds were tested in mice harbouring a chronic
S. mansoni
infection.
Results
Eleven of the 37 compounds active on the larval stage were also highly active on adult worms in vitro (IC
50
= 2.0–7.5 μM). IC
50
values on adult
S. mansoni
decreased substantially in the presence of albumin (7.5–123.5 μM). Toxicity to L6 and MRC cells was moderate. A moderate worm burden reduction of 51.6% was observed for MMV690534, while the other 9 compounds showed low activity. None of the in vivo results were statistically significant (
P
> 0.05).
Conclusions
Phenotypic screening of advanced lead compounds is a simple and resource-low method to identify novel anthelminthics. None of the promising hits of the Stasis Box identified in vitro against
S. mansoni
yielded acceptable worm burden reductions in vivo, which might be due to the high plasma protein binding. Since the in vitro hits interfere with different drug targets, they might provide a starting point for target based screening and structure-activity relationship studies.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ albumins
/ Animals
/ Antimalarials - pharmacology
/ Biomedical and Life Sciences
/ Drug Evaluation, Preclinical
/ Drug Repositioning - methods
/ drugs
/ larvae
/ malaria
/ Mice
/ Schistosoma mansoni - drug effects
/ Schistosomiasis mansoni - drug therapy
/ Schistosomiasis mansoni - parasitology
/ Schistosomiasis mansoni - prevention & control
/ Schistosomicides - administration & dosage
/ Schistosomicides - pharmacology
/ Schistosomicides - therapeutic use
/ Structure-Activity Relationship
/ structure-activity relationships
/ Veterinary Medicine/Veterinary Science
/ Virology
